TKI targeting the PDGFR kinases represent an intriguing approach to treat PAH, as they reverse the remodelling and improve pulmonary haemodynamics [5–7, 9–11, 16]. The gene discussed is PDGFRB; the disease is pulmonary arterial hypertension.